Page 68 - 2018_10-Haematologica-web

X. Jin et al. References
1. Harada H. MDS: Recent progress in molec- ular pathogenesis and clinical aspects. Rinsho Ketsueki. 2017;58(10):1941-1950.
2. Ganguly BB, Banerjee D, Agarwal MB. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the clas- sification and risk stratification of MDS. Blood Cells Mol Dis. 2018;69:90-100.
3. Imran F, Phatak P. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate. Expert Rev Hematol. 2017;10(1):53-64.
4. Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron over- load in patients with lower-risk myelodys- plastic syndrome. Crit Rev Oncol Hematol. 2017;117:57-66.
5. Gattermann N. Iron overload in myelodys- plastic syndromes (MDS). Int J Hematol. 2018;107(1):55-63.
6. Wong C, Wong S, Leitch HA. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfu- sions: Relation to infections and possible benefit of iron chelation therapy. Leuk Res. 2018;67:75-81.
7. Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129(15):2070-2082.
8. Sashida G, Harada H, Matsui H, et al. Ezh2 loss promotes development of myelodys- plastic syndrome but attenuates its predis- position to leukaemic transformation. Nat Commun. 2014;5:4177.
9. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7(12):1063-1066.
10. Unnisa Z, Clark JP, Roychoudhury J, et al.
Meis1 preserves hematopoietic stem cells in mice by limiting oxidative stress. Blood. 2012;120(25):4973-4981.
11. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245.
12. Ramanathan G, Olynyk JK, Ferrari P. Diagnosing and preventing iron overload. Hemodial Int. 2017;21 Suppl 1:S58-S67.
13. Chai X, Li D, Cao X, et al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. Sci Rep. 2015;5:10181.
14. Muto Y, Nishiyama M, Nita A, Moroishi T, Nakayama KI. Essential role of FBXL5- mediated cellular iron homeostasis in maintenance of hematopoietic stem cells. Nat Commun. 2017;8:16114.
15. Mies A, Platzbecker U. Increasing the effec- tiveness of hematopoiesis in myelodysplas- tic syndromes: erythropoiesis-stimulating agents and transforming growth factor-beta superfamily inhibitors. Semin Hematol. 2017;54(3):141-146.
16. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-tha- lassemia. Nat Med. 2014;20(4):398-407.
17. Kim A, Nemeth E. New insights into iron regulation and erythropoiesis. Curr Opin Hematol. 2015;22(3):199-205.
Reactive oxygen species levels control NF- kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
21. Zhang Y, Zhai W, Zhao M, et al. Effects of iron overload on the bone marrow microenvironment in mice. Plos One. 2015;10(3):e120219.
22. Lu W, Zhao M, Rajbhandary S, et al. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol. 2013;91(3):249-261.
23. Chen J, Lu WY, Zhao MF, et al. Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes. Ann Hematol. 2017;96(7):1085-1095.
24. Zheng QQ, Zhao YS, Guo J, et al. Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. Leuk Res. 2017;58:55-62.
25. Arlet JB, Dussiot M, Moura IC, Hermine O, Courtois G. Novel players in beta-tha- lassemia dyserythropoiesis and new thera- peutic strategies. Curr Opin Hematol. 2016;23(3):181-188.
26. Yamamoto M, Tanaka H, Toki Y, et al. Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehy- drogenase. Int J Hematol. 2016;104(4):491-
18. Ivars D, Orero MT, Javier K, et al.
Oxidative imbalance in low/intermediate-
1-risk myelodysplastic syndrome patients:
The influence of iron overload. Clin 501.
Biochem. 2017;50(16-17):911-917.
19. Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S. Unraveling the mech- anisms behind iron overload and ineffec- tive hematopoiesis in myelodysplastic syn-
dromes. Leuk Res. 2017;62:108-115.
20. Meunier M, Ancelet S, Lefebvre C, et al.
27. Zheng Q, Zhao Y, Guo J, et al. Iron over- load promotes mitochondrial fragmenta- tion in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway. Cell Death Dis. 2018;9(5):515.
1634
haematologica | 2018; 103(10)